Rising Diabetes Prevalence Boosts Growth In The Proliferative Diabetic Retinopathy (PDR) Market: Powering Innovation and Expansion in the Proliferative Diabetic Retinopathy (PDR) Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Proliferative Diabetic Retinopathy (PDR) Market Through 2025?
The market for proliferative diabetic retinopathy (PDR) has seen robust expansion in the past few years. The growth is projected to rise from $2.42 billion in 2024 to $2.7 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The increased market size during the historic period is due to a rise in diabetes cases, lifestyle modifications, consumption of unhealthy food habits, government actions, and a growing number of diabetes-induced vision impairments.

What's the Projected Size of the Global Proliferative Diabetic Retinopathy (PDR) Market by 2029?
The market size of proliferative diabetic retinopathy (PDR) is foreseen to expand quickly over the coming years. It's projected to reach $4.02 billion in 2029, soaring at a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this growth during the forecast period include an ageing population, increase in public knowledge and education regarding diabetes, funding for research and development, and a growing need for combined therapies. Key trends foreseen during this forecast period include the progress in diagnostic technologies, new developments in treatment methods, the application of artificial intelligence (AI) for early diagnosis, advancements in gene therapy, and sophisticated retinal imaging.

View the full report here:
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Top Growth Drivers in the Proliferative Diabetic Retinopathy (PDR) Industry: What's Accelerating the Market?
An increase in diabetes cases is predicted to stimulate the proliferative diabetic retinopathy (PDR) market's growth in the future. Diabetes is a long-term health condition identifiable by high blood sugar levels. Diabetic retinopathy, a disease mainly caused by diabetes and can lead to severe damage to the retina, is treatable by a variety of methods that can prevent additional harm and maintain eyesight. For example, the UK's National Health Service (NHS) recorded a significant rise in individuals below 40 having diabetes, escalating from 173,166 cases in 2022 to 216,440 in 2023 in June 2024. This enormous growth underscores an alarming tendency among this age category. The figures suggest a fast rise in the number of diabetes cases among younger people, implying that the increasing prevalence of diabetes propels the proliferative diabetic retinopathy (PDR) market. Proliferative Diabetic Retinopathy (PDR) Market Driver: Obesity's Influence On The Proliferative Diabetic Retinopathy (PDR) Market's Progress

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

What Trends Will Shape the Proliferative Diabetic Retinopathy (PDR) Market Through 2029 and Beyond?
Significant players in the proliferative diabetic retinopathy sector constantly aim to devise innovative therapies to augment treatment efficiency, lessen treatment strain, and amplify patient outcomes. For instance, Biogen, a biotechnology firm from the US, and Samsung Bioepis, a biotech firm from South Korea, debuted Byooviz (ranibizumab-nuna) in the US in June 2022. This marks the first ophthalmology biosimilar in the country. These items are employed for treating patients suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

What Are the Main Segments in the Proliferative Diabetic Retinopathy (PDR) Market?
The proliferative diabetic retinopathy (PDR) market covered in this report is segmented -

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy
2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations
3) By Application: Hospitals, Clinics, Other Applications

Subsegments:
1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

Which Top Companies are Driving Growth in the Proliferative Diabetic Retinopathy (PDR) Market?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Which Regions Will Dominate the Proliferative Diabetic Retinopathy (PDR) Market Through 2029?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.